Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3
出版年份 2012 全文链接
标题
Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3
作者
关键词
-
出版物
LABORATORY INVESTIGATION
Volume 92, Issue 12, Pages 1686-1697
出版商
Springer Nature
发表日期
2012-08-27
DOI
10.1038/labinvest.2012.107
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1 - connective tissue growth factor signalling cascade
- (2011) Jiqian Huang et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Prevalence of chronic kidney disease: a systematic review and meta-analysis
- (2011) T. Anothaisintawee et al. CLINICAL NEPHROLOGY
- Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly: Benefits and Limitations
- (2010) F. Turgut et al. Clinical Journal of the American Society of Nephrology
- Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?
- (2010) Michael R. Lattanzio et al. CURRENT HYPERTENSION REPORTS
- Mechanisms of Tubulointerstitial Fibrosis
- (2010) M. Zeisberg et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Vitamin D Receptor Attenuates Renal Fibrosis by Suppressing the Renin-Angiotensin System
- (2010) Y. Zhang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes
- (2010) Dilip K. Deb et al. KIDNEY INTERNATIONAL
- An integrative view on the role of TGF-β in the progressive tubular deletion associated with chronic kidney disease
- (2010) Omar García-Sánchez et al. KIDNEY INTERNATIONAL
- Epidemiology, Diagnosis, and Management of Depression in Patients With CKD
- (2009) S. Susan Hedayati et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Angiotensin II Induces Connective Tissue Growth Factor and Collagen I Expression via Transforming Growth Factor–β–Dependent and –Independent Smad Pathways
- (2009) Fuye Yang et al. HYPERTENSION
- Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy
- (2009) Xiaoyue Tan et al. KIDNEY INTERNATIONAL
- Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure
- (2009) Isao Matsui et al. KIDNEY INTERNATIONAL
- Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy
- (2009) Robert L. Chevalier et al. KIDNEY INTERNATIONAL
- Renoprotective effects of vitamin D analogs
- (2009) Yan Chun Li KIDNEY INTERNATIONAL
- Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats
- (2009) I. Matsui et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Inhibition of the Renin-Angiotensin System in Chronic Kidney Disease: A Critical Look to Single and Dual Blockade
- (2009) Francesco Locatelli et al. NEPHRON CLINICAL PRACTICE
- Outcomes in CKD: What We Know and What We Need to Know
- (2009) Laura E. Clark et al. NEPHRON CLINICAL PRACTICE
- Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium
- (2008) Juan Kong et al. KIDNEY INTERNATIONAL
- Suppression of renin–angiotensin gene expression in the kidney by paricalcitol
- (2008) Michael Freundlich et al. KIDNEY INTERNATIONAL
- Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice
- (2008) Chunlei Zhou et al. KIDNEY INTERNATIONAL
- Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase
- (2008) Z. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started